Understanding Cerebral Proliferative Angiopathy (CPA)
At a Glance
Cerebral proliferative angiopathy (CPA) is a rare, diffuse network of abnormal brain vessels woven through healthy brain tissue. This makes complete removal risky, so care usually focuses on controlling symptoms, monitoring the brain, and treating a high-risk aneurysm when needed.
Receiving a diagnosis of Cerebral Proliferative Angiopathy (CPA)—sometimes also referred to as Diffuse Proliferative Cerebral Angiopathy—can be a profound shock [1][2]. Because this condition is exceptionally rare, appearing in only about 3% to 4% of patients evaluated for brain vascular malformations in certain institutional cohorts, you may find that many general medical resources do not even mention it [2][3].
It is normal to feel overwhelmed when you are told you have a condition that most people, and even many doctors, have never heard of. This page is designed to help you understand what CPA is, how it differs from more common vascular issues, and why its unique structure requires a specialized approach to care. (Note: Because CPA is so rare, much of the data comes from retrospective case reports and small series, rather than large trials. Percentages discussed are estimates from these groups.)
What is CPA?
CPA is a rare vascular anomaly characterized by a diffuse, widespread web of abnormal blood vessels [1]. Unlike other vascular conditions that might look like a single “knot” or “tangle,” CPA is an angiogenic (blood-vessel-forming) process where the abnormal vessels are woven directly into your healthy brain [4][1].
The most critical thing to understand about CPA is that normal, functional brain tissue—the tissue responsible for your thinking, movement, and senses—is interspersed throughout the abnormal vascular network [1][5]. Because the abnormal vessels and the healthy brain are so closely intertwined, doctors cannot simply remove the entire lesion without risking damage to the healthy brain tissue living inside it [6].
CPA vs. Standard AVM
If you search for information on brain vascular malformations, you will likely find a great deal of literature on Arteriovenous Malformations (AVMs). While CPA was historically grouped with AVMs, researchers now increasingly recognize it as a distinct and separate condition [7][2]. Distinguishing between the two is vital because the treatments used for a standard AVM can be risky if applied to CPA [6][8]. Terminology can overlap across centers (some may use “diffuse AVM”), so expert review of the images is important.
| Feature | Standard AVM | Cerebral Proliferative Angiopathy (CPA) |
|---|---|---|
| Structure | Has a compact nidus (a tight, well-defined knot of vessels) [1]. | A diffuse network; there is typically no single, solid knot [1][9]. |
| Brain Tissue | Typically no functional brain tissue exists inside the compact nidus [5]. | Functional brain tissue is mixed in with the abnormal vessels [1][5]. |
| Blood Flow | Typically “high-flow,” meaning blood rushes quickly from arteries to veins [10]. | Often “low-flow”; early venous drainage is typically minimal or absent compared to classic AVMs [10][11]. |
| Blood Supply | Fed by large, dominant “feeder” arteries [1]. | Fed by many small vessels and often supplemented by transdural blood from the scalp/dura [1][10]. |
How CPA Affects the Brain
Because CPA is often a “low-flow” condition, the brain tissue within and around the network may not receive enough oxygen-rich blood. This is known as ischemia [1]. Over time, this lack of blood flow is thought to cause the brain to try to grow new vessels to compensate, which may contribute to the “proliferative” (growing) nature of the condition [4].
Based on estimates from small cohorts, common ways CPA may present include:
- Seizures: These are reported in approximately 37% of patients [3].
- Headaches: About 45% of patients experience persistent or severe headaches [3].
- Neurological Deficits: This can include transient (temporary) weakness, numbness, or difficulty speaking, often attributed to low blood flow [3][11].
While the risk of a hemorrhage (bleeding in the brain) is generally assessed differently in CPA than in classic AVMs, it is still a possibility that your medical team will monitor closely [3][12].
Navigating a Rare Diagnosis
Finding out you have an “exceptionally rare” condition can feel isolating. Research shows that patients with rare brain vascular malformations often face challenges beyond just physical symptoms, including increased anxiety and a significant impact on their overall quality of life [13][14].
Because CPA is so complex, your care should ideally be managed by a multidisciplinary team—a group of specialists including neurosurgeons, neurologists, and interventional neuroradiologists who have experience with rare vascular anomalies [15]. They will use specialized imaging, such as a Digital Subtraction Angiography (DSA), to map your specific vessel pattern and create a plan that prioritizes protecting your healthy brain tissue [1][16].
In many cases, the goal of management is not to “remove” the CPA, but to manage symptoms like seizures and headaches while using active surveillance to ensure your brain stays healthy [17][18]. If a specific high-risk feature is found, such as a small aneurysm (a bulge in a vessel wall), your team may perform a targeted treatment just for that specific spot [19][20].
Common questions in this guide
What is cerebral proliferative angiopathy (CPA)?
How is CPA different from a typical brain AVM?
What symptoms can CPA cause?
How do doctors confirm a CPA diagnosis?
Does CPA usually require surgery to remove the abnormal vessels?
Which specialists should manage CPA?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
How CPA differs
How is CPA different from a standard AVM, and does that affect my treatment?
Imaging options
Would a Digital Subtraction Angiography scan help map my blood vessels?
Care team
Which specialists should be part of my care team for this condition?
Get notified when new evidence is published on Cerebral proliferative angiopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (20)
- 1
Cerebral Proliferative Angiopathy: Imaging Spectrum and Diagnostic Insights.
Rai P, Chan VEY, Lakhani DA, et al.
AJNR. American journal of neuroradiology 2026; (47(7)):1776-1784 doi:10.3174/ajnr.A9122.
PMID: 41326231 - 2
Clinico-radiological features of cerebral proliferative angiopathy: A large case series from India.
Srivastava T, Gandhi A, Kumar R
The neuroradiology journal 2022; (35(6)):742-750 doi:10.1177/19714009221096816.
PMID: 35614873 - 3
The current clinical picture of cerebral proliferative angiopathy: systematic review.
Yamaki VN, Solla DJF, Telles JPM, et al.
Acta neurochirurgica 2020; (162(7)):1727-1733 doi:10.1007/s00701-020-04289-7.
PMID: 32206904 - 4
Hemorrhagic transformation of ischemic cerebral proliferative angiopathy: A case report.
Xia Y, Yu XF, Ma ZJ, Sun ZW
World journal of clinical cases 2021; (9(20)):5730-5736 doi:10.12998/wjcc.v9.i20.5730.
PMID: 34307632 - 5
Diffuse cerebral angiomatosis associated to basilar apex aneurysm.
Umana GE, Spitaleri A, Fricia M, et al.
British journal of neurosurgery 2023; (37(5)):1215-1219 doi:10.1080/02688697.2020.1836324.
PMID: 33084435 - 6
Cerebral Proliferative Angiopathy in a Child, Five Years after an Intraventricular Hemorrhage and Negative Catheter Angiography.
Singfer U, Baert E, Defreyne L
Journal of the Belgian Society of Radiology 2023; (107(1)):55 doi:10.5334/jbsr.3247.
PMID: 37546522 - 7
Proliferative Angiopathy: A Systematic Review.
Brown NJ, Lien BV, Ehresman J, et al.
Stroke (Hoboken, N.J.) 2024; (4(3)):e001186 doi:10.1161/SVIN.123.001186.
PMID: 41584476 - 8
Diffuse Proliferative Cerebral Angiopathy: A case report and review of the literature.
Rohit , Goh PS
Journal of radiology case reports 2015; (9(9)):1-10 doi:10.3941/jrcr.v9i9.2402.
PMID: 26629303 - 9
Cerebral Proliferative Angiopathy Presenting as Subdural Hematoma: A Case Report and Systematic Literature Review.
Hess RM, Zhang JF, Cappuzzo JM, et al.
World neurosurgery 2022; (164()):281-289 doi:10.1016/j.wneu.2022.05.096.
PMID: 35636668 - 10
Cerebral proliferative angiopathy depicted by four-dimensional computed tomographic angiography: A case report.
Ito S, Kanagaki M, Yoshimoto N, et al.
Radiology case reports 2022; (17(7)):2332-2336 doi:10.1016/j.radcr.2022.03.104.
PMID: 35570862 - 11
Cerebral revascularization in cerebral proliferative angiopathy: a systematic review.
Somji M, McEachern J, Silvaggio J
Neurosurgical focus 2019; (46(2)):E11.
PMID: 30717067 - 12
Recurrent Intraventricular Haemorrhage in Cerebral Proliferative Angiopathy - A Case Report and Review of the Literature.
Gerstl JVE, Bernstock JD, Kappel AD, et al.
The Neurohospitalist 2023; (13(4)):345-350 doi:10.1177/19418744231180046.
PMID: 37701260 - 13
Association of Quality of Life Domains and Clinical Symptoms in Patients With Familial Cerebral Cavernous Malformation.
Tsang C, Nelson J, Vassar R, et al.
Journal of the American Heart Association 2025; (14(17)):e035926 doi:10.1161/JAHA.124.035926.
PMID: 40879027 - 14
Mental health and quality of life in patients with ruptured and unruptured cerebral arteriovenous malformation.
Nascimento VS, Lima AO, Pereira AM, et al.
Arquivos de neuro-psiquiatria 2026; (84(4)):1-7 doi:10.1055/s-0046-1820530.
PMID: 42119987 - 15
Antiepileptic Treatment Strategy in Vascular Malformations.
Giakoumettis D, Margetis K, Stranjalis G, et al.
Current pharmaceutical design 2017; (23(42)):6454-6463 doi:10.2174/1381612823666171027142718.
PMID: 29076420 - 16
Ischemic stroke revealing diffuse cerebral proliferative angiopathy-A case report.
Mojahid A, Mahi NE, Siouri H, et al.
Radiology case reports 2025; (20(7)):3621-3624 doi:10.1016/j.radcr.2025.04.012.
PMID: 40469266 - 17
A Proposed Algorithm for Managing Cerebral Proliferative Angiopathy.
Chen YN, Lee CW, Xiao F, et al.
World neurosurgery 2022; (167()):e360-e369 doi:10.1016/j.wneu.2022.08.009.
PMID: 35961587 - 18
Systematic review of pediatric cerebral proliferative angiopathy.
Yamaki VN, Alwis A, Chowdhury SS, et al.
Journal of neurosurgery. Pediatrics 2026; 1-13 doi:10.3171/2026.4.PEDS25435.
PMID: 42854234 - 19
De novo ruptured intracranial aneurysm associated with cerebral proliferative angiopathy: illustrative case.
Suetsugu H, Okawa S, Ishibashi T, et al.
Journal of neurosurgery. Case lessons 2026; (12(7)).
PMID: 42607334 - 20
Targeted endovascular treatment of haemorrhagic posterior fossa proliferative angiopathy.
Giragani S, Pavunesan SK, Balasubramaniam A
Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences 2018; (24(4)):440-443 doi:10.1177/1591019918761640.
PMID: 29554843
This page explains cerebral proliferative angiopathy and how it differs from a standard AVM for informational purposes only and does not constitute medical advice. Your neurosurgical, neurological, and interventional neuroradiology team should interpret your imaging and recommend care for your situation.